• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Most Adults Support Medicare Coverage of Weight Loss Drugs

News
Article

Obesity affects almost half of adults in the United States.

© Natalia - stock.adobe.com

weight loss drugs © Natalia - stock.adobe.com

In the United States, over 40% of people are affected by obesity and unless the obesity stems from a pre-existing condition, Medicare is prohibited from covering drugs strictly for weight loss due to a Medicare Part D law passed in 2003.

However, 76% of adults in the United States are in favor of Medicare coverage for weight management, according to the National Poll for Healthy Aging, published by the University of Michigan.

Researchers asked roughly 2,700 adults ages 50-80 about their weight, how they managed it and their views on Medicare coverage of weight loss drugs such as Wegovy and Zepbound, which have experienced a 300% increase in demand, CNBC reports.

Almost three-quarters of respondents reported that they had been overweight at some point in their lives. In addition, 92% had tried at least one method to lose weight, with exercise being the most common choice at 89%. Of the people who had never taken a drug strictly for weight loss, 59% said they would be interested in taking one in the future.

“Expanding access to a range of weight management treatments can lead to improvements in health and potentially lower costs,” the authors write. “Many weight loss medications are very expensive, resulting in high potential out-of-pocket costs.”

For example, without coverage, a 30-day supply of Ozempic currently costs around $950, according to GoodRx.

Additional weight loss strategies participants were in favor of covering were dietician sessions (83%), weight loss surgery (73), and gym memberships (65%).

The results of the University of Michigan study were published Dec. 2023. The research was conducted in July and August.

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Related Content
© 2024 MJH Life Sciences

All rights reserved.